Aerie Pharmaceuticals prices IPO at $10, below the range

By Renaissance Capital,

Shutterstock photo

Aerie Pharmaceuticals, a clinical-stage biotech developing treatments for glaucoma, raised $67 million by offering 6.7 million shares at $10, below the range of $12 to $14. Aerie Pharmaceuticals plans to list on the NASDAQ under the symbol AERI. Aerie Pharmaceuticals initially filed confidentially on 5/13/2013. RBC Capital Markets and Stifel acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: AERI

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by